Akanda

Akanda EBIT Margin

The EBIT Margin (Operating Margin) of Akanda (AKAN) as of Oct 27, 2026 is -1,930.99 %. In the previous year, EBIT Margin (Operating Margin) was -523.80 % — a change of 268.65% (lower).

EBIT Margin

-1,930.99 %

YoY

268.65%

Last updated:

EBIT Margin (Operating Margin) of Akanda is 2025 -1,930.99 % . EBIT Margin (Operating Margin) of Akanda was 2024 -523.80 % . It decreases by 268.65% lower compared to the previous year.

For Akanda, the operating (EBIT) margin of -1,931.0% is up versus -6,203.4% a few years ago.

The Akanda EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
-80,787.34 USD
Jan 1, 2021
-6,203.45 USD
Jan 1, 2022
-770.18 USD
Jan 1, 2023
-465.33 USD
Jan 1, 2024
-523.80 USD
Jan 1, 2025
-1,930.99 USD
The Akanda EBIT Margin history
YEAREBIT MarginYoY
-1,930.99 %+268.65%
-523.80 %+12.57%
-465.33 %-39.58%
-770.18 %-87.58%
-6,203.45 %-92.32%
-80,787.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

EBIT Margin (Operating Margin) of Akanda is -1,930.99 % in 2025.

EBIT Margin (Operating Margin) of Akanda changed from -523.80 % to -1,930.99 %, representing a 268.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Akanda since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Akanda

All Key Metrics — Akanda